LB Pharmaceuticals Inc Common Stock (LBRX) Financial Analysis & Valuation | Quarter Chart
LB Pharmaceuticals Inc Common Stock (LBRX)
LBRXPrice: $27.8
Fair Value: 🔒
🔒score
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e... more
Description
Shares
| Market Cap | $797.21M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Heather D. Turner |
| IPO Date | 2025-09-11 | CAGR | — |
| Employees | 16 | Website | lbpharma.us |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LBRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $371.35M | P/E Ratio | -20.44 |
| Forward P/E | -6.68 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.07 |
| P/CF Ratio | -15.21 | P/FCF Ratio | -15.42 |
| EPS | $-1.36 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.18% | ROA | -0.1% |
| ROCE | -0.12% | Current Ratio | 35.68 |
| Quick Ratio | 35.68 | Cash Ratio | 29.4 |
| Debt/Equity | 0.01 | Interest Coverage | 226.94 |
| Altman Z Score | 32.63 | Piotroski Score | 1 |